Erectile Dysfunction in an Urban HIV-Positive Population

2006 ◽  
Vol 20 (2) ◽  
pp. 75-78 ◽  
Author(s):  
Alexander R. Ende ◽  
Vincent Lo Re ◽  
Mark J. DiNubile ◽  
Karam Mounzer
Keyword(s):  
Erectile Dysfunction ◽  
Hiv Positive ◽  
Positive Population

Dare to Care: A Qualitative Content Analysis Regarding Nursing Students’ View on HIV in Vietnam

2018 ◽  
Vol 30 (4) ◽  
pp. 187-194 ◽  
Author(s):  
Johanna Bernhed ◽  
Mimmi Mollstedt ◽  
Kristina Rosengren
Keyword(s):  
Content Analysis ◽  
Nursing Students ◽  
Qualitative Content Analysis ◽  
Hiv Positive ◽  
Evidence Based ◽  
Nursing Skills ◽  
Positive Population

In Vietnam, HIV-positive population, as well as the stigmatization of this disease, is increasing, which affects patients and staff, thus requiring improvement. Nurses have a central role in adopting UNAIDS 90-90-90 vision regarding knowledge and treatment without risk. The aim of this study is to describe nursing students’ experiences with HIV in Hanoi, Vietnam. Interviews with seven nursing students were performed. Data were analyzed using content analysis. The results formed one category, dare to care, and three subcategories: being careful, managing fear, and creating trust. This study highlighted the importance of awareness of values (visualize stigmatization) to develop guidelines (built on evidence-based knowledge) to transform knowledge (theoretical, practical) through nursing skills that are performed to manage fear and create trustful care for HIV-positive patients.

Erectile dysfunction, a cause for concern for HIV positive men?

2018 ◽  
Vol 17 (12) ◽  
pp. e2658
Author(s):  
N. Chirca ◽  
B. Podeanu ◽  
C. Sima ◽  
C. Persu ◽  
O. Sandulescu ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Hiv Positive ◽  
Hiv Positive Men

scholarly journals Seroprevalence of hepatitis B and C infection among the HIV-positive population in Abuja, Nigeria

2013 ◽  
Vol 12 (3) ◽  
Author(s):  
A Tremeau-Bravard ◽  
IC Ogbukagu ◽  
CJ Ticao ◽  
JJ Abubakar
Keyword(s):  
Hepatitis B ◽  
Hiv Positive ◽  
Positive Population

scholarly journals HIV-1 genotyping tropism profile in an HIV-positive population throughout the Russian Federation

2017 ◽  
Vol 4 (1) ◽  
pp. 1311470
Author(s):  
Alexey Lopatukhin ◽  
Dmitry Kireev ◽  
Dmitry Kuevda ◽  
Anastasia Pokrovskaya ◽  
Galina Tsyganova ◽  
...  
Keyword(s):  
Russian Federation ◽  
Hiv Positive ◽  
The Russian Federation ◽  
Positive Population ◽  
Hiv 1

PROGRESSION OF HIV INFECTION IN THE POPULATION OF FRENCH HEMOPHILIACS

1987 ◽  
Author(s):  
Y Sultan
Keyword(s):  
Immune Deficiency ◽  
Hiv Infection ◽  
Elevated Level ◽  
Hiv Positive ◽  
Hiv Seropositivity ◽  
Heat Treated ◽  
Bleeding Episodes ◽  
Positive Population

A national inquiry including 28 hemophilia centers was carried out in France in order to appreciate the epidemiology of HIV infection among hemophilic patients. Information about 1781 patients was obtained with an overall prevalence of 50% seropositive patients. This percentage of HIV seropositivity was unchanged in comparison with 1985 confirming that no seroconversion was observed since the use of heat treated products for bleeding episodes. It is to be noted that there is an important progression in the number of AIDS which increased from 16 hemophiliacs last year to 23 this year with a total of 11 deaths against 7 last year related to this affection. In the' remaining hemophilic population, twenty per cent of HIV positive patients have developed an ARC. For the biological abnormalities related to immune deficiency, it was found that patients with lymphopenia less than 1000 lymphocytes had not progressed and represent 23 patients. Patients with thrombocytopenia less than 150,000 platelets had increased from 29 to 62. Patients with a number of T4 lymphocytes subset less than 400 ha increased from 54 to 110. 22% of HIV positive hemophiliacs had a T4/T8 ratio less than 1 in 1986 in comparison with 11% in 1985.17.5% of HIV positive population showed an elevated level of gamma-globulins above 20 g/liter of plasma against 12.5% last year. The conclusion of the present study is that HIV infectionhas progressed in severity from 1985 to 1986 in the population of multitransfused HIV positive French hemophiliacs.

scholarly journals High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study)

2018 ◽  
Vol 3 ◽  
pp. 83 ◽  
Author(s):  
Fiona V. Cresswell ◽  
Kenneth Ssebambulidde ◽  
Daniel Grint ◽  
Lindsey te Brake ◽  
Abdul Musabire ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Phase Ii ◽  
Controlled Trial ◽  
Standard Of Care ◽  
Hiv Positive ◽  
Current Standard ◽  
Open Label ◽  
Dose Oral ◽  
Randomised Controlled ◽  
Positive Population

Background: Tuberculous meningitis (TBM) has 44% (95%CI 35-52%) in-hospital mortality with standard therapy in Uganda. Rifampicin, the cornerstone of TB therapy, has 70% oral bioavailability and ~10-20% cerebrospinal fluid (CSF) penetration.  With current WHO-recommended TB treatment containing 8-12mg/kg rifampicin, CSF rifampicin exposures frequently fall below the minimal inhibitory concentration for M. tuberculosis. Two Indonesian phase II studies, the first investigating intravenous rifampicin 600mg and the second oral rifampicin ~30mg/kg, found the interventions were safe and resulted in significantly increased CSF rifampicin exposures and a reduction in 6-month mortality in the investigational arms. Whether such improvements can be replicated in an HIV-positive population remains to be determined. Protocol: We will perform a phase II, open-label randomised controlled trial, comparing higher-dose oral and intravenous rifampicin with current standard of care in a predominantly HIV-positive population. Participants will be allocated to one of three parallel arms (I:I:I): (i) intravenous rifampicin 20mg/kg for 2-weeks followed by oral rifampicin 35mg/kg for 6-weeks; (ii) oral rifampicin 35mg/kg for 8-weeks; (iii) standard of care, oral rifampicin 10mg/kg/day for 8-weeks. Primary endpoints will be: (i) pharmacokinetic parameters in plasma and CSF; (ii) safety. We will also examine the effect of higher-dose rifampicin on survival time, neurological outcomes and incidence of immune reconstitution inflammatory syndrome. We will enrol 60 adults with suspected TBM, from two hospitals in Uganda, with follow-up to 6 months post-enrolment. Discussion: HIV co-infection affects the bioavailability of rifampicin in the initial days of therapy, risk of drug toxicity and drug interactions, and ultimately mortality from TBM. Our study aims to demonstrate, in a predominantly HIV-positive population, the safety and pharmacokinetic superiority of one or both investigational arms compared to current standard of care. The most favourable dose may ultimately be taken forward into an adequately powered phase III trial. Trial registration: ISRCTN42218549 (24th April 2018)

Sign in / Sign up

Export Citation Format

Share Document